{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T15:51:21Z","timestamp":1740153081314,"version":"3.37.3"},"reference-count":42,"publisher":"The Journal of Rheumatology","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To evaluate the effect of tofacitinib (TOF) on American College of Rheumatology (ACR) response criteria components in patients with rheumatoid arthritis (RA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>This post hoc analysis pooled data from RA phase III randomized controlled trials (RCTs) assessing TOF 5 or 10 mg BID, adalimumab (ADA), or placebo, with conventional synthetic disease-modifying antirheumatic drugs, and a phase IIIb\/IV RCT assessing TOF 5 mg BID monotherapy, TOF 5 mg BID with methotrexate (MTX), or ADA with MTX. Outcomes included proportions of patients achieving ACR20\/50\/70 responses and \u2265 20\/50\/70% improvement rates in ACR components at week 2 and months 1, 3, and 6; and mean percent improvement in ACR components and Clinical or Simplified Disease Activity Index (CDAI or SDAI) low disease activity or remission rates, at month 3, for ACR20\/50\/70 responders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Across treatment groups, \u2265 20\/50\/70% improvement rates were numerically higher for most physician- vs patient-reported measures. In phase III RCTs, at earlier timepoints, \u2265 50\/70% improvements in patient global assessment of disease activity, pain, and physician global assessment were similar. Among ACR20 responders receiving TOF, mean percent improvements for tender and swollen joint counts were &gt; 70% at month 3. CDAI\/SDAI remission was achieved at month 3 by 27.8\u201345.0% of ACR70 responders receiving TOF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Among ACR20 responders treated with TOF, physician-reported components particularly exceeded 20% response improvement. At month 3, disease state generally did not corroborate ACR70 response criteria. Divergences between physician- and patient-reported measures highlight the importance of identifying appropriate patient-reported outcome targets to manage RA symptoms in clinical practice. (ClinicalTrials.gov: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00847613\">NCT00847613<\/jats:ext-link>\/NCT00856544\/<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00853385\">NCT00853385<\/jats:ext-link>\/NCT02187055)<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.210707","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T13:20:23Z","timestamp":1646140823000},"page":"566-576","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Tofacitinib on Components of the ACR Response Criteria: Post Hoc Analysis of Phase III and Phase IIIb\/IV Trials"],"prefix":"10.3899","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6834-2731","authenticated-orcid":false,"given":"Louis","family":"Bessette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Mysler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2712-1668","authenticated-orcid":false,"given":"Cassandra D.","family":"Kinch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7475-3369","authenticated-orcid":false,"given":"Kenneth","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatjana","family":"Lukic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phu Vinh","family":"On","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6438-8663","authenticated-orcid":false,"given":"Ronald F.","family":"van Vollenhoven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"key":"2022062202351350000_49.6.566.1","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/art.38705","article-title":"Brief report: rheumatoid arthritis response criteria and patient-reported improvement in arthritis activity: is an American College of Rheumatology twenty percent response meaningful to patients?","volume":"66","author":"Ward","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2022062202351350000_49.6.566.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"2022062202351350000_49.6.566.3","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199809)41:9%3C1564::AID-ART6%3E3.0.CO;2-M"},{"key":"2022062202351350000_49.6.566.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2007.02.007"},{"key":"2022062202351350000_49.6.566.5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg072"},{"key":"2022062202351350000_49.6.566.6","doi-asserted-by":"publisher","DOI":"10.1186\/ar1740"},{"key":"2022062202351350000_49.6.566.7","first-page":"S75","article-title":"Scores for all seasons: SDAI and CDAI","volume":"32","author":"Smolen","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2022062202351350000_49.6.566.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207524"},{"key":"2022062202351350000_49.6.566.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.24567"},{"key":"2022062202351350000_49.6.566.10","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20494"},{"key":"2022062202351350000_49.6.566.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.33383"},{"key":"2022062202351350000_49.6.566.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.33419"},{"key":"2022062202351350000_49.6.566.13","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.995875"},{"key":"2022062202351350000_49.6.566.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071"},{"key":"2022062202351350000_49.6.566.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"2022062202351350000_49.6.566.16","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00006"},{"key":"2022062202351350000_49.6.566.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.37816"},{"key":"2022062202351350000_49.6.566.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310476"},{"key":"2022062202351350000_49.6.566.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"key":"2022062202351350000_49.6.566.20","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/art.40803","article-title":"Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty-four-month, phase III study","volume":"71","author":"van der Heijde","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022062202351350000_49.6.566.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31618-5"},{"key":"2022062202351350000_49.6.566.22","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130683"},{"key":"2022062202351350000_49.6.566.23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13075-016-0932-2","article-title":"Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study","volume":"18","author":"Yamanaka","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2022062202351350000_49.6.566.24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2022062202351350000_49.6.566.25","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001395"},{"key":"2022062202351350000_49.6.566.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.24123"},{"key":"2022062202351350000_49.6.566.27","first-page":"318","article-title":"The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2022062202351350000_49.6.566.28","first-page":"685","article-title":"Changes in key laboratory values with tofacitinib 5mg BID treatment in patients with psoriatic arthritis and rheumatoid arthritis [abstract]","volume":"70","author":"Rigby","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"2022062202351350000_49.6.566.29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fmed.2018.00040","article-title":"Common evaluations of disease activity in rheumatoid arthritis reach discordant classifications across different populations","volume":"5","author":"Canh\u00e3o","year":"2018","journal-title":"Front Med"},{"key":"2022062202351350000_49.6.566.30","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000019"},{"key":"2022062202351350000_49.6.566.31","doi-asserted-by":"publisher","DOI":"10.1002\/art.34543"},{"key":"2022062202351350000_49.6.566.32","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-017-1419-5","article-title":"Patient-provider discordance between global assessments of disease activity in rheumatoid arthritis: a comprehensive clinical evaluation","volume":"19","author":"Challa","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2022062202351350000_49.6.566.33","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13075-016-1004-3","article-title":"Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity","volume":"18","author":"Smolen","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2022062202351350000_49.6.566.34","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20132"},{"key":"2022062202351350000_49.6.566.35","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40257-017-0284-y","article-title":"Discordance between physician- and patient-reported disease severity in adults with atopic dermatitis: a US cross-sectional survey","volume":"18","author":"Wei","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"2022062202351350000_49.6.566.36","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/rheumatology\/kex394","article-title":"Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries","volume":"57","author":"Kilcher","year":"2018","journal-title":"Rheumatology"},{"key":"2022062202351350000_49.6.566.37","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000232"},{"key":"2022062202351350000_49.6.566.38","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.3390\/jcm8091394","article-title":"Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM","volume":"8","author":"Fautrel","year":"2019","journal-title":"J Clin Med"},{"key":"2022062202351350000_49.6.566.39","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001131"},{"key":"2022062202351350000_49.6.566.40","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001040"},{"key":"2022062202351350000_49.6.566.41","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13075-020-02324-7","article-title":"Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib","volume":"22","author":"Strand","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2022062202351350000_49.6.566.42","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111543"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.210707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T09:38:31Z","timestamp":1655890711000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.210707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,1]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.3899\/jrheum.210707"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.210707","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"type":"print","value":"0315-162X"},{"type":"electronic","value":"1499-2752"}],"subject":[],"published":{"date-parts":[[2022,3,1]]}}}